Sunday, November 8, 2026

USD/JPY Jumps By 1% In The Last 5 Sessions

ViaNews Editorial Team

September 20, 2024

USD/JPY Jumps By 1% In The Last 5 Sessions

(VIANEWS) - USD/JPY (USDJPY) has been up by 1.39% for the last 5 sessions. At 20:06 EST on Thursday, 19 September, USD/JPY (USDJPY) is $142.78.

USD/JPY's yearly highs and lows, it's 2.293% up from its 52-week low and 11.833% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/JPY's Forex is considered to be oversold (<=20).

Previous days news about USD/JPY (USDJPY)

  • Usd/jpy slides further below 142.00 amid softer usd, focus remains on fed decision. According to FXStreet on Wednesday, 18 September, "This, in turn, validates the near-term negative outlook for the USD/JPY pair and supports prospects for an extension of the recent well-established downtrend.", "The USD/JPY pair attracts fresh sellers during the Asian session on Wednesday and slides back below the 142.00 mark in the last hour, eroding a part of the overnight gains and stalling its recovery from the lowest level since July 2023 touched earlier this week. "
  • Usd/jpy: markets are bracing for volatile moves after FOMC – OCBC. According to FXStreet on Wednesday, 18 September, "FOMC decision should see USD/JPY more volatile, OCBC FX analysts Frances Cheung and Christopher Wong note.", "FOMC decision should see USD/JPY trade wild into and post-decision, press conference."
  • Usd/jpy price forecast: slips from 4-day peak, hovers below 142.00. According to FXStreet on Wednesday, 18 September, "The USD/JPY downtrend remains in place, but the Federal Reserve's decision to cut rates by a smaller or larger size could trigger different reactions. ", "If the Fed lowers rates by 25 basis points, this could be bullish for the USD/JPY and push prices toward the September 17 high at 142.47, which, if cleared, will expose the 143.00 figure."

More news about USD/JPY (USDJPY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com